SLU-PP-332 (250mcg Capsule) – Dosage Protocol
Contents
Quickstart Highlights
SLU-PP-332 (also referenced in primary literature as SLU-PP-332) is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ). Preclinical research has explored its ability to activate gene pathways associated with aerobic exercise adaptation, mitochondrial biogenesis, and fatty acid oxidation. To date, no human clinical trials have been completed, and all published efficacy data come from controlled murine studies using intraperitoneal injection.
This page describes a research-use-only oral framework for the 250 mcg capsule format. There is no validated oral bioavailability data for SLU-PP-332 in humans or animals. The protocol below is provided as an educational reference only.
- Evidence base: Preclinical murine studies (intraperitoneal route only)
- Form covered on this page: 250 mcg oral capsule, 100 capsules per bottle
- Reference murine dose: ~1250–2500 mcg/day, split into two doses (IP route)
- Educational oral framework: 250–1000 mcg/day, split across the day
- Storage: Sealed bottle at room temperature, away from light and moisture
- Status: For research use only. Not for human consumption.
Dosing Schedule (Capsule Form)
Educational reference schedule for the 250 mcg oral capsule. No published clinical or veterinary data validate oral dosing in any species; ranges below are illustrative only.
Capsule Dosing Schedule
| Phase | Daily Dose | Capsules/Day | Split |
|---|---|---|---|
| Weeks 1–2 (Introduction) | 250 mcg | 1 capsule | Morning |
| Weeks 3–6 (Standard) | 500 mcg | 2 capsules | 1 AM, 1 PM |
| Weeks 7–8 (Extended) | 750–1000 mcg | 3–4 capsules | Split across the day |
| Weeks 9–12 (Optional washout) | — | 0 capsules | 4-week off-cycle |
Cycle length: 8 weeks on, 4 weeks off is a common research-protocol pattern for ERR agonist studies. Continuous, uninterrupted use beyond 8 weeks has not been characterized in any published model.
Important: This schedule is for educational and research purposes only. It is not medical advice. For research use only. Not for human consumption.
Protocol Overview
- Evidence status: Preclinical only — no human studies
- Mechanism of interest: Pan-agonism of ERRα/β/γ; downstream mitochondrial biogenesis and fatty acid oxidation
- Form: Oral capsule, 250 mcg per capsule
- Frequency: Once to four times daily (split dosing)
- Cycle: 8 weeks on, 4 weeks off (educational framework)
- Storage: Sealed, room temperature, dry, light-protected
Dosing Protocol
- Weeks 1–2: 250 mcg once daily, taken with a small amount of dietary fat to support absorption of the lipophilic compound
- Weeks 3–6: 500 mcg daily, split into morning and afternoon doses (12 hours apart where practical)
- Weeks 7–8: Optional escalation to 750–1000 mcg daily, split across 3–4 doses
- Weeks 9–12: Off-cycle washout
- Timing: Dosing alongside meals containing fat is theorized to support absorption, but no oral pharmacokinetic data exist to confirm this
- Consistency: Maintain the same intra-day intervals across the cycle
Storage Instructions
- Store the sealed bottle at room temperature (15–25 °C / 59–77 °F)
- Keep in a dry environment, away from direct light and humidity
- Do not refrigerate or freeze the capsules
- Replace the desiccant pack if included and visibly degraded
- Discard if capsules show discoloration, fusion, or shell breakdown
Important Notes
- SLU-PP-332 has no human safety, efficacy, or pharmacokinetic data
- All efficacy data come from animal studies using a non-oral route
- The compound is investigational and is not approved by any regulatory body for human use
- Maintain detailed research logs of dosing, timing, and observations
- Discontinue immediately and document any unexpected observations
- Intended strictly for in vitro and research-model use; not for human consumption, diagnostic, or therapeutic use
How This Works
SLU-PP-332 binds and activates the estrogen-related receptors (ERRα, ERRβ, ERRγ), a family of orphan nuclear receptors that regulate genes involved in energy metabolism. In preclinical models, ERR activation:
- Stimulates expression of genes associated with aerobic exercise adaptation
- Enhances mitochondrial biogenesis and oxidative respiration
- Increases fatty acid oxidation in skeletal and cardiac muscle
- Supports endurance capacity and metabolic flexibility
Because of these effects, the compound has been described in the literature as an “exercise mimetic” — a molecule that may reproduce certain biochemical signatures of physical training without the training stimulus itself.
Preclinical Observations
Findings observed in murine studies include:
- Endurance capacity: Increased treadmill running time and distance
- Mitochondrial function: Enhanced respiration and ATP production in muscle
- Cardiac metabolism: Improved fatty acid utilization in models of heart failure
- Renal function: Reduced mitochondrial dysfunction and inflammation in aging kidney models
- Metabolic profile: Improved glucose handling in metabolic syndrome models
These results are limited to animal models using intraperitoneal injection. Translation to oral administration or to human physiology is unknown.
Research Considerations
- Outcomes may vary with diet, environmental conditions, and protocol design
- ERR agonist effects appear to be synergistic with concurrent exercise in animal models
- Compound handling and capsule storage should be standardized across a study
- Co-administration with other ERR-active or mitochondria-targeting compounds has not been characterized
Administration
SLU-PP-332 in the 250 mcg capsule form is taken orally. Capsules require no preparation and can be taken directly from the bottle.
- Swallow each capsule whole with water
- Do not crush, chew, or open the capsule shell
- Take with food containing dietary fat where feasible
- Maintain a dosing log noting time, capsule count, and any observations
- Do not exceed the daily total outlined in the educational framework above
Recommended Source
We recommend Fit Aminos for high-purity research compounds.
Compound 332 Capsules — 250 mcg/Capsule — 100 Capsules
Why Fit Aminos?
- High-purity, lab-tested batches with per-batch quality verification
- Consistent handling and preparation processes designed to support reproducible research
- Transparent sourcing and dependable fulfillment for research-grade compounds
Important Note
This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment.
SLU-PP-332 remains an investigational compound with no human clinical data. The oral capsule format has no published pharmacokinetic, safety, or efficacy data in any species. For research use only. Not for human consumption, diagnostic, or therapeutic use.
References
ACS Chemical Biology (2023)
— Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Journal of Pharmacology and Experimental Therapeutics (2024)
— A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Circulation (2024)
— Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
American Journal of Pathology (2023)
— Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney